Profilo
Mitchell Golbus was a Professor at The University of California, San Francisco from 1981 to 1994.
He was also the President & Chief Medical Officer at Diamics, Inc. Dr. Golbus holds a doctorate degree from the University of Illinois.
Precedenti posizioni note di Mitchell Golbus
| Società | Posizione | Fine |
|---|---|---|
Diamics, Inc.
 Diamics, Inc. Medical SpecialtiesHealth Technology Diamics Inc. is a medical technology company located in the San Francisco Bay Area. As an innovator in women’s health, the company develops breakthrough cancer diagnostic systems. Diamics’ management team has an extensive track record of success in the medical device, diagnostics and biotechnology industries. The company’s mission is to constantly improve cancer screening diagnostics and provide solutions for unmet medical needs in women’s health. Diamics has two products in near term (6-12 months) development timelines. One product, the TouchPap™, focuses on improving the ubiquitous Pap test and is scheduled for launch in 2009. Following on the heels of this launch will be products aimed at the rapidly expanding molecular diagnostics market, specifically targeting HPV and cervical cancer. | Presidente | 15/10/2013 |
| The University of California, San Francisco | Corporate Officer/Principal | 01/01/1994 |
Formazione di Mitchell Golbus
| University of Illinois | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Diamics, Inc.
Diamics, Inc. Medical SpecialtiesHealth Technology Diamics Inc. is a medical technology company located in the San Francisco Bay Area. As an innovator in women’s health, the company develops breakthrough cancer diagnostic systems. Diamics’ management team has an extensive track record of success in the medical device, diagnostics and biotechnology industries. The company’s mission is to constantly improve cancer screening diagnostics and provide solutions for unmet medical needs in women’s health. Diamics has two products in near term (6-12 months) development timelines. One product, the TouchPap™, focuses on improving the ubiquitous Pap test and is scheduled for launch in 2009. Following on the heels of this launch will be products aimed at the rapidly expanding molecular diagnostics market, specifically targeting HPV and cervical cancer. | Health Technology |
- Borsa valori
- Insiders
- Mitchell Golbus
